CommercialCoverageMedium impact
Molecular Genomic Profiling for Cancers of Unknown Primary
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Pathology·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes that molecular genomic profiling (including gene expression profiling and comprehensive genomic profiling) for cancers of unknown primary is considered investigational and not covered. The policy affects oncology billing for tissue of origin testing and treatment guidance for cancers of unknown primary.
Action Required
Immediately: Billing team must deny coverage and inform providers that CPT codes 81479, 81504, and 81519 for molecular genomic profiling in cancers of unknown primary are considered investigational by BCBS Mississippi. Update billing system to flag these codes as non-covered when used for tissue of origin testing. Providers should obtain alternative coverage verification or discuss self-pay options with patients.